GW-803430

GW-803430
Clinical data
ATC code	none;
Identifiers
	IUPAC name 6-(4-chlorophenyl)-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-3H-thieno[3,2-d]pyrimidin-4-one;
CAS Number	515141-51-2;
PubChem CID	9826520;
ChemSpider	8002263;
UNII	4R0136W1PR;
CompTox Dashboard (EPA)	DTXSID70199490 ;
ECHA InfoCard	100.230.542
Chemical and physical data
Formula	C25H24ClN3O3S
Molar mass	482.00 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C5CCCN5CCOc3ccc(cc3OC)-n1cnc2cc(sc2c1=O)-c(cc4)ccc4Cl;
	InChI InChI=1S/C25H24ClN3O3S/c1-31-22-14-19(8-9-21(22)32-13-12-28-10-2-3-11-28)29-16-27-20-15-23(33-24(20)25(29)30)17-4-6-18(26)7-5-17/h4-9,14-16H,2-3,10-13H2,1H3; Key:MWULMTACIBZPGN-UHFFFAOYSA-N;
	(verify)

GW-803430 (GW-3430) is a drug used in scientific research and is a selective non-peptide antagonist at the melanin concentrating hormone receptor MCH₁. In animal studies it has anxiolytic, antidepressant and anorectic effects.^[1]^[2]

References

^ Chaki S, Kanuma K. Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders. Drugs of the Future. 2007;32(9):809.
^ Gehlert DR, Rasmussen K, Shaw J, Li X, Ardayfio P, Craft L, Coskun T, Zhang HY, Chen Y, Witkin JM (May 2009). "Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression". The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 429–38. doi:10.1124/jpet.108.143362. PMID 19182070.

Template:Neuropeptidergics

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

[1] Chaki S, Kanuma K. Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders. Drugs of the Future. 2007;32(9):809.

[pmid19182070-2] Gehlert DR, Rasmussen K, Shaw J, Li X, Ardayfio P, Craft L, Coskun T, Zhang HY, Chen Y, Witkin JM (May 2009). "Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression". The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 429–38. doi:10.1124/jpet.108.143362. PMID 19182070.

[1]

[2]

v t e Anxiolytics (N05B)
5-HT_1ARTooltip 5-HT1A receptor agonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptor PAMsTooltip positive allosteric modulators	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Hypnotics	Zopiclone
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone) TCAsTooltip Tricyclic antidepressants (e.g., clomipramine^#) TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Antipsychotics	Quetiapine Flupentixol
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III